Last update 21 Nov 2024

18F-PSMA-1007

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals

Synonyms-

Target

PSMA

Mechanism

PSMA modulators(Prostate-specific membrane antigen modulators)

Therapeutic Areas

NeoplasmsUrogenital DiseasesOther Diseases

Active Indication

Prostatic CancerLocalized Prostate CarcinomaRecurrent Prostate Carcinoma+ [1]

Inactive Indication

Glioblastoma

Originator Organization

German Cancer Research Center

Active Organization

Centre For Probe Development & Commercialization

ABX advanced biochemical compounds GmbH

German Cancer Research Center

Inactive Organization

Radboud University Medical Center

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure

Molecular FormulaC49H55FN8O16

InChIKeyRFFFFGRYVZESLB-CXODGJKXSA-N

CAS Registry2093321-19-6

Boost your research with our ADC technology data.

view full example data

Gene Sequence

Sequence Code 527975753

Clinical Trials associated with 18F-PSMA-1007

NCT06122584 / RecruitingPhase 3

Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

This study assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Start Date13 Jun 2024

Sponsor / Collaborator

ABX advanced biochemical compounds GmbH

CTIS2023-504026-19-01 / Recruiting

Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer - ABX-CT-302EU/EAGLE-i

Start Date05 Jun 2024

Sponsor / Collaborator

ABX advanced biochemical compounds GmbH

ChiCTR2400088372 / RecruitingEarly Phase 1IIT

18F-PSMA-1007 PET/MRI guided precise radiotherapy for high-risk prostate cancer: a prospective, multicenter cohort study

Start Date12 Apr 2024

Sponsor / Collaborator

Shanghai East Hospital

100 Clinical Results associated with 18F-PSMA-1007

100 Translational Medicine associated with 18F-PSMA-1007

100 Patents (Medical) associated with 18F-PSMA-1007

Literatures (Medical) associated with 18F-PSMA-1007

01 Jul 2023·Clinical nuclear medicine

Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET/CT in Patients With Localized Prostate Cancer: A Systematic Review and Meta-analysis.

Review

Author: Chen, Li-Yu ; Huang, Ya-Yao ; Wang, Yuh-Feng ; Huang, Ya-Ting ; Chang, Chi-Wei ; Lo, Chun-Yu ; Huang, Yi-Hsiu

PURPOSEMultiparametric MRI (mpMRI) has been promoted as an auxiliary diagnostic tool for prostate biopsy. However, prostate-specific membrane antigen (PSMA) including 68 Ga-PSMA-11, 18 F-DCFPyL, and 18 F-PSMA-1007 applied PET/CT imaging was an emerging diagnostic tool in prostate cancer patients for staging or posttreatment follow-up, even early detecting. Many studies have used PSMA PET for comparison with mpMRI to test the diagnostic ability for early prostate cancer. Unfortunately, these studies have shown conflicting results. This meta-analysis aimed to compare the differences in diagnostic performance between PSMA PET and mpMRI for detecting and T staging localized prostatic tumors.METHODSThis meta-analysis involved a systematic literature search of PubMed/MEDLINE and Cochrane Library databases. The pooling sensitivity and specificity of PSMA and mpMRI verified by pathological analysis were calculated and used to compare the differences between the 2 imaging tools.RESULTSOverall, 39 studies were included (3630 patients in total) from 2016 to 2022 in the current meta-analysis and found that the pooling sensitivity values for localized prostatic tumors and T staging T3a and T3b of PSMA PET were 0.84 (95% confidence interval [CI], 0.83-0.86), 0.61 (95% CI, 0.39-0.79), and 0.62 (95% CI, 0.46-0.76), respectively, whereas those of mpMRI were found to be 0.84 (95% 0.78-0.89), 0.67 (95% CI, 0.52-0.80), and 0.60 (95% CI, 0.45-0.73), respectively, without significant differences ( P > 0.05). However, in a subgroup analysis of radiotracer, the pooling sensitivity of 18 F-DCFPyL PET was higher than mpMRI (relative risk, 1.10; 95% CI, 1.03-1.17; P < 0.01).CONCLUSIONSThis meta-analysis found that whereas 18 F-DCFPyL PET was superior to mpMRI at detecting localized prostatic tumors, the detection performance of PSMA PET for localized prostatic tumors and T staging was comparable to that of mpMRI.

17 May 2023·Cancers

Intra-Individual Comparison of Physiologic [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis.

Article

Author: Albers, Peter ; Mattes-György, Katalin ; Giesel, Frederik L ; Radtke, Jan Philipp ; Mori, Yuriko ; Antke, Christina ; Mamlins, Eduards ; Schimmöller, Lars ; Antoch, Gerald ; Novruzov, Emil ; Niegisch, Günter ; Dabir, Mardjan ; Schmitt, Dominik ; Beu, Markus

BACKGROUNDSeveral studies indicate, particularly in the case of [18F]PSMA-1007, a relatively high rate of detection of ganglia in PSMA PET imaging. Ganglia are an integral part of the sympathetic portion of the autonomous nervous system. To date, no studies have directly compared [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 ganglionic uptake intra-individually and analyzed the underlying molecular and physical mechanisms of different detection rates. With this monocentric retrospective study, we sought to evaluate the intra-individual physiological ganglion uptake of these different PSMA ligands in evidence-based imaging for prostate cancer.METHODSOur cohort consists of 19 male patients (median age 72 ± 9 with a range of 56-85) with biochemical recurrence of prostate cancer who underwent both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT in our clinic on the same scanner per standard care between March 2015 and March 2022. Tracer uptake was quantified according to maximum standardized uptake value (SUV_max) for both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT scans. Ganglia-to-background ratios (GBRs) were determined to quantify the image contrast through dividing the SUV_max of the ganglia by the background value (SUV_max of blood pool in the descending aorta, fatty tissue, and skeletal muscle in gluteal region). We used descriptive analyses for demographics and tumor characteristics and performed two-way repeated-measures ANOVA (analysis of variance) for SUV metrics including GBR measurements.RESULTSIn total, we examined 101 ganglia with [¹⁸F]PSMA-1007 scanning, localized mostly in pairs as stellate, coeliac, and sacral, of which 76 were also detected with [⁶⁸Ga]Ga-PSMA-11 PET/CT scanning. There was no statistically significant difference in PSMA uptake in terms of SUV_max between [¹⁸F]PSMA-1007 and [⁶⁸Ga]Ga-PSMA-11 (p value: 0.052). In contrast, the comparison of GBRs revealed a higher detectability rate of ganglia with [¹⁸F]PSMA-1007 imaging (p < 0.001). Furthermore, a separate comparison of ganglia with respect to their anatomical location also demonstrated statistically significant differences both within and between [¹⁸F]PSMA-1007 and [⁶⁸Ga]Ga-PSMA-11 PET/CT scans.CONCLUSIONGiven the impression of more accentuated [¹⁸F]PSMA-1007 uptake in ganglia compared with ⁶⁸Ga-labelled counterparts, our study demonstrated that the better detectability of ganglia is not due to more intense [¹⁸F]PSMA-1007 uptake by these small structures but to much more favorable physical properties of the radionuclide ¹⁸F. The most relevant limitations of our study are its retrospective design and the small patient cohort.

01 May 2023·Journal of Nuclear Medicine

Unspecific¹⁸F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer

Article

Author: Berliner, Christoph ; Telli, Tugce ; Stuschke, Martin ; Seifert, Robert ; Nader, Michael ; Barbato, Francesco ; Opitz, Marcel ; Fendler, Wolfgang P ; Hadaschik, Boris ; Umutlu, Lale ; Herrmann, Ken

¹⁸F-PSMA-1007 PET is used in the management of patients with prostate cancer. However, recent reports indicate a high rate of unspecific bone uptake (UBU) with ¹⁸F-PSMA-1007, which may lead to a false-positive diagnosis. UBU has not been evaluated thoroughly. Here, we evaluate the frequency of UBU and bone metastases separately for ¹⁸F-PSMA-1007 and ⁶⁸Ga-PSMA-11 in biochemical recurrence (interindividual comparison). Additionally, we investigate UBU seen in ¹⁸F-PSMA-1007 through follow-up examinations (intraindividual comparison) using ⁶⁸Ga-PSMA-11 PET, bone scintigraphy, and MRI. Methods: First, all patients (n = 383) who underwent ⁶⁸Ga-PSMA-11 PET between January 2020 and December 2020 and all patients (n = 409) who underwent ¹⁸F-PSMA-1007 PET between January 2020 and November 2021 due to biochemical recurrence were included for an interindividual comparison of bone metastases and UBU rate. In a second approach, we regarded all patients with UBU in ¹⁸F-PSMA-1007, characterized by focal bone uptake with an SUV_max > 4 and prostate-specific antigen (PSA) ≤ 5 ng/mL, who underwent additional ⁶⁸Ga-PSMA-11 PET (n = 17) (interindividual comparison). Of these, 12 patients also had bone scintigraphy and whole-body MRI within a 1- to 5-wk interval. Bone uptake seen on ¹⁸F-PSMA-1007 but not on any of the other 4 modalities (CT, MRI [n = 1], bone scanning, and ⁶⁸Ga-PSMA-11 PET) was recorded as false-positive. Results: Patients scanned with ¹⁸F-PSMA-1007 PET had a significantly higher rate of UBU than those scanned with ⁶⁸Ga-PSMA-11 (140 vs. 64; P < 0.001); however, the rate of bone metastases was not significantly different (72 vs. 64; P = 0.7). In the intraindividual comparison group, workup by CT, MRI, bone scanning, and ⁶⁸Ga-PSMA-11 PET resulted in a positive predictive value for ¹⁸F-PSMA-1007 focal bone uptake (mean SUV_max, 6.1 ± 2.9) per patient and per lesion of 8.3% and 3.6%, respectively. Conclusion: In patients with PSA ≤ 5 ng/mL and SUV > 4 at biochemical recurrence, most ¹⁸F-PSMA-1007 focal bone uptake is likely to be false-positive and therefore due to UBU. In the case of low clinical likelihood of metastatic disease, ¹⁸F-PSMA-1007 bone uptake without morphologic surrogate should be assessed carefully with regard to localization and clinical context. However, the rate of bone metastases was not higher with ¹⁸F-PSMA-1007 in the clinical routine, indicating that experienced reporting physicians adjust for UBU findings.

News (Medical) associated with 18F-PSMA-1007

10 Sep 2024

·www.globenewswire.com

Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain

PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI® is now available for patients with prostate cancer. PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Benoit Woessmer, PET Europe CEO at Curium commented, “The availability of PYLCLARI® in Spain is an important milestone for patients with prostate cancer and underscores our dedication to improving the choice of diagnostic PET radiopharmaceuticals. As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, we are proud that the availability of PYLCLARI® continues to grow and now covers seven countries including Austria, France, Germany, Greece, Italy, the Netherlands, and Spain.” In Spain, prostate cancer is one of the most common cancers among men with around 30,000 new cases diagnosed nationwide every year. PYLCLARI® is being produced by Curium at two sites in Madrid and one site in Sevilla, ensuring timely and efficient distribution across the country. For more information about PYLCLARI®: www.pylclari.com In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018. About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com For more information:Ross Bethell, VP, Head of Global CommunicationsCuriumcommunications@curiumpharma.com

Drug ApprovalRadiation Therapy

11 Jul 2024

·www.drugs.com

18F-PSMA-1007 PET/CT Superior to MRI for Staging Prostate Cancer

THURSDAY, July 11, 2024 -- For men undergoing locoregional staging of prostate cancer, fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed tomography ( 18 F-PSMA-1007 PET/CT) is superior to multiparametric magnetic resonance imaging (MRI), according to a study published online July 1 in JAMA Oncology to coincide with the annual meeting of the Canadian Urological Association, held from June 29 to July 1 in Victoria. Nikhile Mookerji, M.D., from the University of Alberta in Edmonton, Canada, and colleagues determined the accuracy of 18 F-PSMA-1007 PET/CT compared to multiparametric MRI in the primary locoregional staging of intermediate- and high-risk prostate cancers in the Next Generation Trial, a phase 2 study. Patients underwent all imaging studies and radical prostatectomies at two tertiary care hospitals; 134 of 150 eligible men with prostate cancer underwent radical prostatectomy. The researchers found that compared with MRI, PSMA PET was significantly superior for the accurate identification of the final pathological tumor stage (45 versus 28 percent, respectively). In addition, PSMA PET was significantly superior for the correct identification of the dominant nodule (94 versus 83 percent), laterality (64 versus 44 percent), and extracapsular extension (75 versus 63 percent) compared with MRI but was not significantly superior for correct identification of seminal vesicle invasion. "Future research should address the accuracy of combining PET/CT and MRI as well as cost effectiveness of PET/CT for the primary staging of men with prostate cancer," the authors write. Abstract/Full Text More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultPhase 2Radiation Therapy

17 Jun 2024

·www.globenewswire.com

Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer

First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that with first doses in Austria administered in May 2024, it is making strong progress in the European roll-out of PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Benoit Woessmer, PET Europe CEO at Curium commented, “Today’s news that PYLCLARI® is now available to patients with prostate cancer in Austria is a testament to Curium's dedication to and ambition for the country and health care professionals in Austria. PYLCLARI® is currently available in six European countries – with more countries planned for first doses in 2024. We are extremely proud to be improving the choice of diagnostic radiopharmaceuticals available to physicians to better diagnose prostate cancer.” In Austria, prostate cancer is one of the most common cancers among men with around 7,000 new cases diagnosed nationwide every year. PYLCLARI® is being produced in Austria by Curium at its Linz premises, with first doses administered at KABEG Klinikum Klagenfurt and a hospital in Linz. Authorization to produce PYLCLARI® at Curium’s Linz site was granted by Austria’s Österreichische Agentur für Gesundheit und Ernährungssicherheit in October 2023. For more information about PYLCLARI®: www.pylclari.com In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018. About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com For more information:Ross Bethell, VP, Head of Global CommunicationsCuriumcommunications@curiumpharma.com

Drug ApprovalRadiation Therapy

100 Deals associated with 18F-PSMA-1007

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 3	FR	ABX advanced biochemical compounds GmbH	13 Jun 2024
Prostatic Cancer	Phase 3	ES	ABX advanced biochemical compounds GmbH	13 Jun 2024
Localized Prostate Carcinoma	Phase 3	US	ABX advanced biochemical compounds GmbH	08 Sep 2021
Localized Prostate Carcinoma	Phase 3	NL	ABX advanced biochemical compounds GmbH	08 Sep 2021
Localized Prostate Carcinoma	Phase 3	CH	ABX advanced biochemical compounds GmbH	08 Sep 2021
Recurrent Prostate Carcinoma	Phase 3	CA	Centre For Probe Development & Commercialization	21 Dec 2020
Glioblastoma	Phase 1	NL	Radboud University Medical Center	12 Nov 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2023	Not Applicable	Prostatic Cancer	-	18F-PSMA-1007 (ISUP GG1)	hczltlezyj(jouldjckfm) = simczyxaaz clpduzwlcp (osliiiunww )	-	28 Aug 2023
				18F-PSMA-1007 (ISUP GG2)	hczltlezyj(jouldjckfm) = uvyntmyace clpduzwlcp (osliiiunww )
ASCO_GU2023	Not Applicable	Non-metastatic prostate cancer	154	<sup>18</sup>F-PSMA1007 (<sup>68</sup>Ga-PSMA-11)	vupkhzdlfq(aivdegdbcf) = uauyyfhtfx puuijyzgul (nrxlsnlcsg )	-	21 Feb 2023
SNMMI2021	Not Applicable	Recurrent Prostate Carcinoma	-	18F-PSMA-100718 F-PSMA-1007 (18F-PSMA-1007)	kygpzgnyfz(sspzalnzlm) = pafwrjoiqq vsyjxkocqu (nhbcvvxjbt )	-	18 May 2021
				18 F-PSMA-1007 (Al18F-PSMA-HBED-CC)	kygpzgnyfz(sspzalnzlm) = prjmcmtven vsyjxkocqu (nhbcvvxjbt )
ASTRO	Not Applicable	Prostatic Cancer	-	68Ga-PSMA-11-PET	(hxosqwslwq) = fjmmvrnvoc faxvfarkpq (jbyqgfozaw ) View more	-	01 Nov 2020
				18F-PSMA-1007-PET	(hxosqwslwq) = ywlevdhxnn faxvfarkpq (jbyqgfozaw ) View more
SNMMI2019	Not Applicable	Non-metastatic prostate cancer	-	18 F-PSMA-1007 (18F-PSMA-1007 positive)	bscjozuoje(iixfvxpagn) = qupknkqjnn mpbhdzujqm (ustufgtowe, 0.08) View more	-	21 May 2019
				18 F-PSMA-1007 (18F-PSMA-1007 negative)	(ejrpjszcys) = vpritahyod ecyevvvxdy (zeftucnqkj, 0.20 - 0.97)
SNMMI2018	Not Applicable	-	-	18F-PSMA-100718 F-PSMA-1007 (18F-PSMA-1007)	zjsouwdptv(jfbwiyryow) = > 1,000 yauymosnbk (lafstjejit ) View more	-	23 May 2018
SNMMI2017	Not Applicable	-	-	18F-PSMA-100718 F-PSMA-1007 (18F-PSMA-1007)	mahtiaiqqt(zasegbyerg) = yjeidweawf wprnhalhta (soktskwmjq ) View more	-	24 May 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis